Bannerbild German Brest Group

GBG Research at ESMO Breast Cancer 2019

02.05.2019

Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.

#1080: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: pooled analysis based on the GBG database

  • Session: Type: Proffered Paper session; Title: Best abstracts session; 3.05.2019, 16:45 - 17:00 (oral presentation)
  • First author: J. Huober J; Universitätsfrauenklinik Ulm, Germany

#15P: Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: pooled analysis of 484 patients from three prospective multicentre GBG trials

  • Session: Type: Poster display session; Title: Poster lunch; 3.05.2019, 12:15 - 13:00 (poster)
  • First author: P. Jank; Charité Universitaetsmedizin Berlin, Germany

#25P: Expression of ER, PR, HER2 and Ki-67 in the neoadjuvant GeparX trial - comparison of central immunohistochemistry (IHC) with an automated cartridge-based system for mRNA assessment

  • Session: Type: Poster display session; Title: Poster lunch; 03.05.2019; 12:15 - 13:00 (poster)
  • First author: C. Denkert; Institut für Pathologie Philipps-Universität Marburg, Germany

#122TiP: GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

  • Session: Early breast cancer: Neoadjuvant therapy; 3.05.2019; 12:15 – 13:00 (poster, trial in progress)
  • First author: S. Loibl; GBG, Neu-Isenburg, Germany

https://www.esmo.org/Conferences/ESMO-Breast-Cancer-2019/Programme

News

  • 01.02.2019 Results of the GeparOcto trial

    We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.

    Mehr ...
  • 18.01.2019 Prof. Loibl unter den meist zitierten Wissenschaftlern in 2018

    Prof. Dr. Sibylle Loibl gehört im Jahr 2018 mit Ihrer Arbeit im Bereich der Brustkrebsforschung zu den 1% der am meisten zitierten Wissenschaftlern.

    Mehr ...
  • 17.12.2018 Results of an interim analysis from KATHERINE trial

    We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.

    Mehr ...
  • 16.12.2018 GBG-Jahrestreffen - Anmeldung möglich

    GBG-Jahrestreffen - Anmeldung möglich

    Die Anmeldung zum GBG Jahrestreffen, sowie zum AGO-Meeting 2019 in Frankfurt ist ab sofort möglich.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd